Anzeige
Mehr »
Login
Donnerstag, 26.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Während die Wall Street über Krypto-ETFs debattiert, liefert dieses Unternehmen 1.000?% RENDITE!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DFA6 | ISIN: SE0017486103 | Ticker-Symbol: WY60
Frankfurt
23.12.24
15:29 Uhr
0,336 Euro
+0,006
+1,82 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
INIFY LABORATORIES AB Chart 1 Jahr
5-Tage-Chart
INIFY LABORATORIES AB 5-Tage-Chart

Aktueller Chart INIFY LABORATORIES Aktie

Chart vergleichen mit:

Firmenname, WKN, ISIN oder Aktien-Kürzel

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%
Chart-Typ:
Zeitraum:
 
INIFY LABORATORIES AB-Investoren interessieren sich auch für diese Wertpapiere
GeneDx Reports Third Quarter 2024 Financial Results and Business HighlightsSTAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third...
► Artikel lesen
GeneDx to Participate in Fall Investor ConferencesGeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences this fall:...
► Artikel lesen
GeneDx Reports Second Quarter 2024 Financial Results and Business HighlightsSTAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the second...
► Artikel lesen
PROCEPT BioRobotics Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA GuidanceSAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative...
► Artikel lesen
PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate CancerA Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of Aquablation Therapy in Men with Grade Group 1 to 3 Localized Prostate Cancer Represents Potential Paradigm Shift in...
► Artikel lesen
PROCEPT BioRobotics Announces FDA Clearance of the HYDROS Robotic System, the Next-Generation, AI-Powered Platform for Aquablation TherapySAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative...
► Artikel lesen
Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary IndicationNanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication...
► Artikel lesen
Nano-X Imaging LTD.: Nanox Receives FDA Clearance for HealthCCSng V2.0, Upgraded Version of Advanced AI Cardiac Solution Empowering Physicians in Assessment of Coronary Artery CalciumHealthCCSng V2.0 introduces additional 'zero calcium' categorization of coronary artery calcium (CAC) and generates a numerical calcium score with corresponding CAC detection category output Marks...
► Artikel lesen
Nano-X Imaging LTD.: Nanox Announces Second Quarter of 2024 Financial Results and Provides Business UpdateAccelerated the deployment of Nanox ARC in the US market, Submitted a new 510k application to the FDA to expand Nanox.ARC indications to include general use, including chest Nanox.AI Receives FDA...
► Artikel lesen